ClinicalTrials.gg
Not yet recruitingNCT07857252ALACARTEUpdated Oct 5, 2026

Patient Choice Between Antibiotics and Appendectomy in Uncomplicated Appendicitis (FRENCH 47 - ALACARTE)

A Phase 2 interventional study of Shared decision-making and amoxicillin-clavulanate in Acute Appendicitis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Appendicitis with a site in France — 7 open to participants now, 7 under way, 2 of them phase 3. Appendicitis · France.

Planned enrollment
6th of 13
560 · median 473
Started
2026
with 2 others
Phase 2
Only one
of the 18
Registered
18th of 18
by date
Lead sponsor
2 of 18
Assistance Publique - Hôpitaux de Paris

Among the 18 studies in Appendicitis with a site in France, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2, and was the 18th registered.

Appendicitis

421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.

Browse Appendicitis studies →

Open to participants now

7 of the 18 studies in Appendicitis with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Appendicitis with a site in France, or all of them as a file.
02

Study summary

The ALACARTE study evaluates a strategy in which patients with acute uncomplicated appendicitis are given the choice between appendectomy and antibiotic therapy alone. The investigators hypothesize that giving patients the choice of treatment could reduce treatment regret without compromising safety, particularly by not increasing the risk of complicated appendicitis.Treatment regret will be assessed one year after the randomization. A public health benefit is also anticipated through cost reduction, as antibiotic therapy alone is expected to be less costly than surgery.

Read the detailed description

Appendectomy provides definitive treatment for acute appendicitis. However, antibiotic therapy alone represents an alternative treatment option for patients with acute uncomplicated appendicitis.Patients are centrally randomized in a 1:1 ratio to either the "Patient Preference Treatment" group or the "Systematic Appendectomy" group.In the "Patient Preference Treatment" group, patients receive information through a video, followed by a discussion with the investigator and a reflection period of at least 30 minutes. Patients may then choose between antibiotic therapy alone and appendectomy. Patients who do not make a treatment choice undergo appendectomy.The study is based on the hypothesis that giving patients a choice of treatment could reduce treatment regret without compromising safety, particularly by not increasing the risk of complicated appendicitis.Treatment regret will be assessed one year after the randomization.

03

Conditions studied

  • Acute Appendicitis

Keywords

  • Acute uncomplicated appendicitis
  • Appendectomy
  • Patient preference
  • Treatment choice
  • Regret
  • Antibiotic therapy
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patients aged 18-70 years
  2. Diagnosis of uncomplicated AA established by the investigator surgeon that relies on clinico-biological suspicion of acute AA confirm by care radiological tests (US and/or CT and/or MRI) including appendix diameter >6.0mm. and without:

    1. Diffuse peritonitis on clinical exam (i.e., rigid abdomen / four quadrant peritonitis);
    2. Radiologic findings of:

    i. Free air ii. Walled off fluid collection concerning for an abscess iii. Significant amounts of intra-abdominal fluid throughout abdomen (i.e.,more than trace fluid) iv. Extent of inflammation or adjacent organ involvement on radiologic, appendicular plastron on radiologic imaging

  3. Surgery expected within 24 hours after diagnosis
  4. Patient able to read and understand the language and content of the study documents and agreeing to adhere to the protocol requirements
  5. Patient with internet access at home and a valid email address who declares being able to complete an online questionnaire
  6. Signature of the written form by the patient
  7. Affiliation to a French health insurance scheme

Exclusion Criteria:

Exclusion Criteria :

  1. Appendicolith visible on radiological tests (US and/or CT and/or MRI)
  2. Appendix diameter >15mm (risk factor of appendicular tumor) visible on radiological tests (US and/or CT and/or MRI)
  3. Suspicion of a tumor of the appendix on the imaging exam ((US and/or CT and/or MRI) by the radiologist: (mucocele, pseudomyxoma, neuroendocrine tumor, adenocarcinoma of the appendix, another type of tumor…)
  4. Evidence of severe sepsis or septic shock (e.g., new presumed sepsis-related organ dysfunction, elevated lactate, and/or fluid unresponsive hypotension)
  5. Severe or uncontrolled comorbidities, such as hepatic cirrhosis, heart failure, acute or chronic kidney failure (estimated \<60mL/min), concurrent hemodialysis or peritoneal dialysis, or treatments using indwelling venous catheters, presence of active cancer or a malignant hemopathy, anticoagulant treatments
  6. Recent (within 90 days) placement of surgical implant (e.g., pacemaker, joint prosthesis, mechanical valve) or indwelling Left Ventricular Assist Device
  7. Immunodeficiency (e.g., \<500/mm3, chronic drugs, long term , or known AIDS [ \<200/mm3 or AIDS-defining illness assessed by patient history)
  8. History of inflammatory bowel disease (Crohn disease, or ulcerative colitis or indeterminate colitis)
  9. Ongoing antibiotic therapy for another infection
  10. Abdominal/pelvic surgery in the past month
  11. to Amoxicillin, clavulanic acid and penicillins
  12. History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to another beta-lactam (e.g., a cephalosporin, carbapenem, or monobactam).
  13. History of icterus/liver damage related to amoxicillin/clavulanic acid
  14. Allergy to any of the listed in section 6.1 of SmPC
  15. History of AA treated by antibiotics or appendectomy
  16. Pregnant* or breast-feeding women
  17. Participation in another interventional study or being in the exclusion period at the end of a previous study.
  18. Mental or cognitive impairment rendering the patient unable to understand study information or to provide informed consent.
  19. Patient being a relative of the investigator or of a member of the research team directly involved in the trial (assistant doctors, pharmacists, nurses, or study coordinators).
  20. Adult under guardianship or deprived of freedom
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
560 participants (estimated)

Study arms

  • Experimental
    Intervention arm : Patient preference treatment

    Participants receive standardized information and are then allowed to choose between antibiotic therapy alone and appendectomy. Patients who do not express a preference undergo appendectomy.

    Other: Shared decision-making · Drug: amoxicillin-clavulanate · Procedure: Appendectomy

  • Active comparator
    Control arm : Appendectomy

    Participants undergo appendectomy as the standard treatment for acute uncomplicated appendicitis

    Procedure: Appendectomy

Interventions

  • OtherShared decision-making

    Participants receive standardized information and are then allowed to choose between antibiotic therapy alone and appendectomy. Patients who do not express a preference undergo appendectomy.

  • Drugamoxicillin-clavulanate

    Drug pages: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Clavulanic AcidStudies of Clavulanic AcidClavulanic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    amoxicillin-clavulanate (PO or IV 1 gx3/day for patients \<90 kg or 1 gx4/day for patients ≥90 kg)

    Also known as: amoxicillin-clavulanic acid

  • ProcedureAppendectomy

    Appendectomy

06

What researchers measure

Primary outcomes

  1. Regret about the initial treatment

    The presence of regret about the initial treatment will be evaluated through a specific questionnaire completed online by the patient. The question will be: "You were initially treated for your appendicitis (infection of the appendix) either by surgery with removal of the appendix (appendectomy) or by antibiotic therapy alone without surgery initially. Do you regret the treatment you received? YES - NO." The surgeon will be blinded to the answer.

    Time frame: 12 month after the randomization

Secondary outcomes

  1. Patient's symptom persistence or recurrence

    Proportion of patients with at least one symptom persistence or recurrence at 12 months : Symptom persistence defined by participants who report the persistence of significant abdominal pain (≥4 with intensity quantified using the numeric pain rating scale from 0 to 10), the persistence of a perceived or measured fever \> 38.0°C, or the persistence of chills.

    Time frame: at 12 months

  2. Patient's quality of life at 12 months.

    Quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). questionnaire using the French value set for scoring heath states and fulfilled by the participants (Responses are recorded on a 5-point scale: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems or unable to perform the activity.)

    Time frame: at 12 months

  3. Regret concerning the treatment received

    The regret at 12 months assessed by the validated decisional regret scale. This standardized scale allows quantifying treatment regret by a score ranging from 0 for no regret to 100 for maximum regret.

    Time frame: at 12 months

  4. Diagnosis of a complicated AA

    Complicated AA is defined by a localized or diffuse peritonitis, abscessed appendicitis, necrotized appendicitis or appendicular plastron as determined by the surgeon through intraoperative findings or through clinical examination and abdominal imaging (CT-scan or MRI or abdominal US) in case of non-surgical management.

    Time frame: within 12 months after randomization

  5. Positive bacteriological examination of intrabdominal fluid harvested during surgery

    Time frame: during surgery

  6. Overall 12-months morbidity

    The occurrence of at least one of the following complication during the 12 months after randomization: site-related infectious complications (defined as incisional infections or organ-space infections \[abscesses\]), percutaneous drainage procedure, surgical intervention (for complication after appendectomy or appendectomy for recurrent appendicitis after antibiotic), ileus requiring the placement of a nasogastric tube, wound hernia, small bowel obstruction requiring emergency consultation or hospitalization, adverse event related to the known side effects of the administered antibiotic therapy.

    Time frame: 12 months

  7. Unscheduled medical encounter

    by at least one of the following events: * Unscheduled consultations or readmissions at hospital related to the AA or to its treatment reported by the participant. * Among patients treated initially by appendectomy: proportion of patient with unscheduled surgical procedures due to delayed complications after appendicitis or appendectomy. * Among patients treated initially by antibiotics only: proportion of occurrence of appendectomy (with or without appendicitis on the surgical specimen) or unscheduled surgical procedure other than appendectomy due to complications related to the AA. * Among patients treated initially by antibiotics only: proportion of recurrence or persistent AA proven by pathological examination of the appendix after appendectomy or by an imaging (CT or ultrasound or MRI) in case of nonsurgical management.

    Time frame: within 12 months after randomization

  8. Diagnosis of an appendicular tumor

    Presence of an appendicular tumor (benign or malignant) defined by the anatomopathological diagnosis on the operative specimen of appendectomy.

    Time frame: within 12 months after randomization

  9. Cost per quality-adjusted life year (QALY) gained

    Economic evaluation comparing patients who had the option to select their treatment versus patients who underwent systematic appendectomy. Results will be expressed as cost per QALY gained at 12 months.

    Time frame: at 12 months

  10. Cost per additional patient without complication

    Economic evaluation comparing patients who had the option to select their treatment versus patients who underwent systematic appendectomy. Results will be expressed as cost per additional patient without complication at 12 months.

    Time frame: at 12 months

Other outcomes

  1. Patient's regret

    assessed by the answer at the question : " : "You were initially treated for your appendicitis (infection of the appendix) either by surgery with removal of the appendix (appendectomy) or by antibiotic therapy alone without surgery initially. Do you regret the treatment you received? YES - NO."

    Time frame: at 1 and 6 months

  2. Treatment regret assessed by the validated decisional regret scale.

    This standardized scale allows quantifying treatment regret by a score ranging from 0 for no regret to 100 for maximum regret.

    Time frame: at 1 and 6 months

  3. Persistence of appendicitis-related symptoms assessed by abdominal pain, fever, or chills

    Symptom's persistence defined by participants who report the persistence of a significant abdominal pain (≥4 with intensity quantified using the numeric pain rating scale from 0 to 10), the persistence of a perceived or measured fever \> 38.0°C, or the persistence of chills.

    Time frame: at 1 and 6 months

  4. Patient's quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) at 1 month and 6 months

    Quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). questionnaire using the French value set for scoring heath states and fulfilled by the participants (Responses are recorded on a 5-point scale: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems or unable to perform the activity.)

    Time frame: at 1 and 6 months

  5. Number of participants reporting each potential cause of treatment regret, assessed using a 13-item self-administered questionnaire

    Potential causes of treatment regret assessed using a 13-item self-administered questionnaire evaluating information and understanding before treatment, decision-making process, treatment experience, and social and economic consequences. Each item is scored from 1 (strongly agree) to 5 (strongly disagree).

    Time frame: at 12 months

  6. 12-month overall length of stay

    Time frame: within 12 months after the randomization

  7. 12-month duration of sick leave related to the AA or to its treatment.

    Time frame: within 12 months after the randomization

  8. Therapeutic adherence to the treatment (Among patients initially treated by antibiotics only)

    Among patients initially treated by antibiotics only: Therapeutic adherence to the treatment defined by the complete intake of the prescribed antibiotic doses over a duration of 7 days. This criterion will be assessed by the following question at 1 month: "Regarding the antibiotic treatment prescribed, have you?: 1) Taken all prescribed doses, 2) Missed some doses but at least 75% of the treatment was taken, 3) Missed some doses but between 25% and 75% of the treatment was taken, 4) Missed some doses with less than 25% of the treatment taken"

    Time frame: at 1 month

  9. Pain intensity at the time of the treatment decision assessed by the Numeric Pain Rating Scale (patient preference treatment group)

    Pain intensity on an 11-point Numeric Pain Rating Scale from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more pain. Presence or absence of fever, nausea and vomiting recorded at the same time.

    Time frame: at inclusion

  10. Main motivation for the treatment decision assessed by a self-administered questionnaire (patient preference treatment group)

    Self-administered questionnaire completed after the treatment decision: main reason for choosing antibiotic therapy alone or appendectomy (8 options), or for choosing not to decide (4 options).

    Time frame: at inclusion

  11. Decisional conflict assessed by the Decisional Conflict Scale (patient preference treatment group)

    16-item validated Decisional Conflict Scale. Total score from 0 (no decisional conflict) to 100 (extremely high decisional conflict); higher scores indicate greater decisional conflict.

    Time frame: at inclusion

  12. Healthcare access and lifestyle assessed by a self-administered questionnaire (patient preference treatment group)

    Self-administered online questionnaire on travel time to the general practitioner and to the hospital, living conditions, occupational status, educational level, use of primary care and sources of health information.

    Time frame: at 1 month

07

Study locations

1 site
  • Department of digestive and general surgery, APHP Saint-Antoine Hospital City Paris
    Paris, 75012, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Nov 2029, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857252
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Maxime COLLARD, MD, PhD
Contact
maxime.collard@aphp.fr
+33.6.26.54.86.19
Thibault VORON, MD, PhD
Contact
thibault.voron@aphp.fr
+33.6.65.68.83.30
Maxime COLLARD
principal investigator · APHP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Amoxicillin · Clavulanic Acid

Start the discussion